Effect of tumor length on clinical stage for non-operative esophageal squamous cell carcinoma patients——multicenter retrospective data analysis (3JECROG R-01D)
10.3760/cma.j.issn.1004-4221.2019.07.003
- VernacularTitle:非手术食管鳞癌病变长度对临床分期影响——Ⅱ/Ⅲ期根治性放疗患者多中心回顾性分析(3JECROG R-01D)
- Author:
Zhiguo ZHOU
1
;
Xin WANG
;
Lan WANG
;
Junqiang CHEN
;
Wencheng ZHANG
;
Xiaomin WANG
;
Xiaolin GE
;
Wenbin SHEN
;
Miaomiao HU
;
Qianqian YUAN
;
Yonggang XU
;
Chongli HAO
;
Shuai QIE
;
Na LU
;
Qingsong PANG
;
Ping WANG
;
Yidian ZHAO
;
Xinchen SUN
;
Kaixian ZHANG
;
Gaofeng LI
;
Ling LI
;
Miaoling LIU
;
Yadi WANG
;
Chen LI
;
Shuchai ZHU
;
Zefen XIAO
;
Chun HAN
;
Xueying QIAO
Author Information
1. 河北医科大学第四医院放疗科
- Keywords:
Esophageal neoplasms/radiotherapy;
Tumor length;
Clinical stage;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2019;28(7):490-494
- CountryChina
- Language:Chinese
-
Abstract:
Objective To retrospectively analyze the effect of tumor length on the prognosis in stage Ⅱ/Ⅲ esophageal squamous cell carcinoma (ESCC) patients treated with definitive radiotherapy and to evaluate the role of tumor length in clinical stage for non-operative ESCC patients.Methods The data of 2 086 ESCC patients who were treated with definitive radiotherapy from 2002 to 2016 in 10 hospitals (3JECROG) were analyzed.The effect of tumor length on overall survival (OS) was analyzed and stratified analysis of tumor length was done in different stages of ESCC.Results The median OS and median progression-free survival (PFS) time of the whole group were 25.6 months and 18.2 months respectively.The Cox multivariate analysis showed that treatment moda,aga,alinical stage and tumor length were independent prognostic factors.The median,1-,3-,and 5-year OS were 28.9 months,77.3％,45.0％,and 36.3％ versus 21.9 months,69.9％,37.9％,and 28.1％ for patients with ≤ 5 cm and patients ＞ 5 cm respectively (P＜0.05).For stage Ⅱ patienta,abe median OS were 42.1 and 38.9 months respectively in ≤ 5 cm group and＞5 cm group (P=0.303).And for stage Ⅲ patienta,abe median OS were 23.9 and 19.3 months respectively in ≤5 cm group and＞5 cm group (P＜0.001).The median OS with N1was 24.1 and 18.4 montha,aespectively in ≤5 cm group and＞5 cm group (P＜0.001).Conclusions The tumor length was an independent prognostic factor for stage Ⅱ/Ⅲ patients treated definitive radiotherapy.The tumor length may be helpful in clinical staging of ESCa,aspecially for stage Ⅲ and N1.
